Education
About Us
Working with TipRanks
Follow Us
InMed Pharmaceuticals (INM)
NASDAQ:INM
RESEARCH TOOLSreports
INM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.72 - $15.69
Previous CloseN/A
Volume49.03K
Average Volume (3M)6.36M
Market Cap
$4.08M
Enterprise Value$1.14B
Total Cash (Recent Filing)$4.72B
Total Debt (Recent Filing)$419.35M
Price to Earnings (P/E)―
Beta2.72
Next Earnings
Sep 19, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.94
Shares Outstanding1,207,186
10 Day Avg. Volume11,250,748
30 Day Avg. Volume6,362,645
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)3.75
Price to Sales (P/S)0.00
P/FCF Ratio-6.09
Enterprise Value/Market Cap279.19
Enterprise Value/Revenue0.33
Enterprise Value/Gross Profit-0.18
Enterprise Value/Ebitda-0.18
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
InMed Pharmaceuticals News
PremiumMarket News
3 Penny Stocks to Watch Now, 6/3/25
PremiumCompany Announcements
InMed’s INM-901 Shows Promise in Reducing Alzheimer’s Neuroinflammation
PremiumCompany Announcements
InMed Pharmaceuticals Faces Quorum Issue at Special MeetingOptions Prices
Currently, No data available
---
Ownership Overview
32.04% Insiders
<0.01% Other Institutional Investors
67.96% Public Companies and Individual Investors
INM FAQ
What was InMed Pharmaceuticals’s price range in the past 12 months?
InMed Pharmaceuticals lowest stock price was $1.72 and its highest was $15.69 in the past 12 months.
What is InMed Pharmaceuticals’s market cap?
InMed Pharmaceuticals’s market cap is $4.08M.
When is InMed Pharmaceuticals’s upcoming earnings report date?
InMed Pharmaceuticals’s upcoming earnings report date is Sep 19, 2025 which is in 81 days.
How were InMed Pharmaceuticals’s earnings last quarter?
InMed Pharmaceuticals released its earnings results on May 12, 2025. The company reported -$1.94 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.94.
Is InMed Pharmaceuticals overvalued?
According to Wall Street analysts InMed Pharmaceuticals’s price is currently Overvalued.
Does InMed Pharmaceuticals pay dividends?
InMed Pharmaceuticals does not currently pay dividends.
What is InMed Pharmaceuticals’s EPS estimate?
InMed Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InMed Pharmaceuticals have?
InMed Pharmaceuticals has 1,207,186 shares outstanding.
What happened to InMed Pharmaceuticals’s price movement after its last earnings report?
InMed Pharmaceuticals reported an EPS of -$1.94 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 14.912%.
Which hedge fund is a major shareholder of InMed Pharmaceuticals?
Currently, no hedge funds are holding shares in INM
Company Description
InMed Pharmaceuticals
InMed Pharmaceuticals (INM) is a biopharmaceutical company focused on the research, development, and manufacturing of rare cannabinoids and novel cannabinoid-based therapeutics. Operating within the pharmaceutical and biotechnology sectors, InMed is dedicated to harnessing the therapeutic potential of cannabinoids to address various unmet medical needs. The company's core products and services include cannabinoid-based drug development programs and the production of pharmaceutical-grade cannabinoids for prescription drug applications.
Technical Analysis
Galmed Pharmaceuticals
―
Scinai Immunotherapeutics
―
Revelation Biosciences
―
GRI Bio
―
Shuttle Pharmaceuticals Holdings, Inc.
―